RIGGED: Same people slamming hydroxychloroquine for coronavirus are publishing pro-remdesivir studies in fake science journals
August 9, 2020
(Natural News – Ethan Huff) As you may already know, The Lancet recently retracted a May 22 article it published claiming that the generic anti-malaria drug hydroxychloroquine (HCQ) is ineffective against the Wuhan coronavirus (COVID-19). Not only were the claims made in this now-retracted paper false, but it turns out that the very same people who put it together were also busy publishing other studies pushing the anti-viral drug remdesivir as the preferable alternative to HCQ.
A “tiny U.S. based company” named Surgisphere, we reported, had generated “flawed data” that led to the result that its “hidden” authors wanted to see, which is basically that HCQ is useless in terms of remedying the pandemic.
While it initially appeared as though Surgisphere was directly to blame for the fiasco, a closer look at the aforementioned “hidden” authors has revealed Brigham and Women’s Hospital, under the guidance of Harvard University professor Mandeep Mehra, as the true culprit.
Mehra, who currently holds the Harvey Distinguished Chair of Medicine at Brigham and Women’s Hospital, issued an apology for his involvement in the scam, which he claimed was a mistake. But it turns out that Mehra was quietly involved in an elaborate scheme designed to “kill” the legitimacy of HCQ as a cure for the Wuhan coronavirus (COVID-19).
At the very same time that Mehra was working on his fake study, another study, also out of Brigham and Women’s Hospital, was also taking place at the direction of Dr. Francisco Marty, who was working on behalf of Gilead Sciences Inc., the manufacturer of remdesivir, to push its drug instead of HCQ.
“Brigham and Women’s Hospital began enrolling patients in two clinical trials for Gilead’s antiviral medication remdesivir,” a report about the trial explains. “The Brigham is one of multiple clinical trial sites for a Gilead-initiated study of the drug in 600 participants with moderate coronavirus disease (COVID-19) and a Gilead-initiated study of 400 participants with severe COVID-19.”
“If the results are promising, this could lead to FDA approval, and if they aren’t, it gives us critical information in the fight against COVID-19 and allows us to move on to other therapies.”
Though Mehra was not directly involved with this latter study, his colleague Marty was, and they had to both know what was going on because Mehra had participated in a conference sponsored by Gilead back in early April “as part of the Covid-19 debate.”
https://taketheredpillpeople.com/news/2020/08/09/rigged-same-people-slamming-hydroxychloroquine-for-coronavirus-are-publishing-pro-remdesivir-studies-in-fake-science-journals-2/